Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 5/2014

01.05.2014 | Vascular Biology(RS Rosenson, Section Editor)

The Endothelium in Diabetic Nephropathy

verfasst von: Richard E. Gilbert

Erschienen in: Current Atherosclerosis Reports | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Diabetes is characterised by widespread endothelial cell dysfunction that underlies the development of both the micro- and macrovascular complications of the disease, including nephropathy, cardiomyopathy, and non-proliferative retinopathy. In the kidney, major changes are noted in glomerular endothelial cell structure in their fenestrations and glycocalyx. These changes, along with endothelial cell loss and capillary rarefaction in both the glomerulus and tubulointerstitium, lead to the progressive loss of glomerular filtration that render diabetes the most common cause of end-stage renal disease in much of the developed world. New treatments in diabetes that directly address the abnormal structure and function of the endothelial cell are desperately needed.
Literatur
1.•
Siddiqi FS, Advani A. Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes. 2013;62:3647–55. This is an excellent up-to-date review on the role of the podocyte in maintaining endothelial cell integrity in diabetes. PubMedCrossRef
2.
Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2009;296:F947–56.PubMedCentralPubMedCrossRef
3.
Nielsen S, Kwon T-H, Fenton RA, Praetorius J: Anatomy of the Kidney. In Brenner and Rector's the Kidney al. MWTe, Ed. Philadelphia, PA, Elsevier, 2012, p. 326-352.
4.
Haraldsson B, Jeansson M. Glomerular filtration barrier. Curr Opin Nephrol Hypertens. 2009;18:331–5.PubMedCrossRef
5.
Obeidat M, Obeidat M, Ballermann BJ. Glomerular endothelium: a porous sieve and formidable barrier. Exp Cell Res. 2012;318:964–72.PubMedCrossRef
6.
Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007;56:2155–60.PubMedCrossRef
7.•
Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int. 2012;82:1010–7. This is an important study that explores the relationship between glomerular capillary endothelial fenestration and declining kidney fuction in diabetic nephropathy in humans. PubMedCentralPubMedCrossRef
8.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707–16.PubMedCentralPubMedCrossRef
9.
Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A. 2007;104:14448–53.PubMedCentralPubMedCrossRef
10.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.PubMedCrossRef
11.
Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342–8.PubMedCentralPubMedCrossRef
12.
Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88:451–87.PubMedCrossRef
13.
Haraldsson B, Nystrom J. The glomerular endothelium: new insights on function and structure. Curr Opin Nephrol Hypertens. 2012;21:258–63.PubMedCrossRef
14.
Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest. 1982;47:177–84.PubMed
15.
van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int. 1992;41:115–23.PubMedCrossRef
16.
van den Born J, van Kraats AA, Bakker MA, Assmann KJ, Dijkman HB, van der Laak JA, et al. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy. Diabetologia. 1995;38:1169–75.PubMedCrossRef
17.
Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int. 2000;57:385–400.PubMedCrossRef
18.
Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH. Glomerular filtration is normal in the absence of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. Nephrol Dial Transplant. 2009;24:2044–51.PubMedCentralPubMedCrossRef
19.
van den Hoven MJ, Wijnhoven TJ, Li JP, Zcharia E, Dijkman HB, Wismans RG, et al. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int. 2008;73:278–87.PubMedCrossRef
20.••
Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 2012;61:208–16. This study not only examines the role of heparanase in diabetic nephropathy using knockout mice but also shows the therapeutic effects of administering a specific heparanase inhibitor. PubMedCentralPubMedCrossRef
21.
van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006;70:2100–8.PubMed
22.
Kuwabara A, Satoh M, Tomita N, Sasaki T, Kashihara N. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia. 2010;53:2056–65.PubMedCentralPubMedCrossRef
23.
van den Hoven MJ, Waanders F, Rops AL, Kramer AB, van Goor H, Berden JH, et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant. 2009;24:2637–45.PubMedCrossRef
24.
Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, et al. Collaborative study G: Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23:123–30.PubMedCentralPubMedCrossRef
25.
Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, et al. Collaborative study G: Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58:729–36.PubMedCrossRef
26.
Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrol (Carlton). 2005;10:167–73.CrossRef
27.
Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol. 2004;15:68–78.PubMedCrossRef
28.
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219–26.PubMedCrossRef
29.
Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53:2646–55.PubMedCentralPubMedCrossRef
30.
Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55:1127–32.PubMedCrossRef
31.
Mauer S, Steffes M, Ellis E, Sutherland D, Brown D, Goetz F. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74:1143–55.PubMedCentralPubMedCrossRef
32.
Laplante P, Sirois I, Raymond MA, Kokta V, Beliveau A, Prat A, et al. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ. 2010;17:291–303.PubMedCrossRef
33.
Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation. 2000;101:2618–24.PubMedCrossRef
34.
Aoki M, Nata T, Morishita R, Matsushita H, Nakagami H, Yamamoto K, et al. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension. 2001;38:48–55.PubMedCrossRef
35.
Nakagami H, Morishita R, Yamamoto K, Yoshimura SI, Taniyama Y, Aoki M, et al. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes. 2001;50:1472–81.PubMedCrossRef
36.
Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18:391–9.PubMedCrossRef
37.
Behl Y, Krothapalli P, Desta T, Roy S, Graves DT. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes. 2009;58:917–25.PubMedCentralPubMedCrossRef
38.
Kageyama S, Yokoo H, Tomita K, Kageyama-Yahara N, Uchimido R, Matsuda N, et al. High glucose-induced apoptosis in human coronary artery endothelial cells involves up-regulation of death receptors. Cardiovasc Diabetol. 2011;10:73.PubMedCentralPubMedCrossRef
39.
Li Volti G, Seta F, Schwartzman ML, Nasjletti A, Abraham NG. Heme oxygenase attenuates angiotensin II-mediated increase in cyclooxygenase-2 activity in human femoral endothelial cells. Hypertension. 2003;41:715–9.PubMedCrossRef
40.
Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res. 1996;19:191–5.PubMedCrossRef
41.
Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008;74:867–72.PubMedCrossRef
42.
Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806–16.PubMedCrossRef
43.
Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229–39.PubMedCrossRef
44.••
Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE. Vegfa protects the glomerular microvasculature in diabetes. Diabetes. 2012;61:2958–66. This study shows that upregulation of VEGFA protects the kidney microvasculature from diabetes-induced injury and that reduction of VEGFA in diabetes may be harmful. PubMedCentralPubMedCrossRef
45.
Kelly DJ, Hepper C, Wu LL, Cox AJ, Gilbert RE. Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrol Dial Transplant. 2003;18:1286–92.PubMedCrossRef
46.
Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36–47.PubMedCrossRef
47.
Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 2004;43:636–50.PubMedCrossRef
48.
Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 2007;18:1765–76.PubMedCrossRef
49.
Gilbert RE, McNally PG, Cox A, Dziadek M, Rumble J, Cooper ME, et al. SPARC gene expression is reduced in early diabetes related kidney growth. Kidney Int. 1995;48:1216–25.PubMedCrossRef
50.
Advani A, Gilbert RE: The endothelium in diabetic nephropathy. Seminars in nephrology 2011:In Press 2011.
51.
Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia. 2008;51:1296–305.PubMedCrossRef
52.
Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010;33:1097–102.PubMedCentralPubMedCrossRef
53.
Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:195–9.PubMedCrossRef
54.
Dessapt C, Karalliedde J, Hernandez-Fuentes M, Martin PP, Maltese G, Dattani N, et al. Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care. 2010;33:875–7.PubMedCentralPubMedCrossRef
55.
Makino H, Okada S, Nagumo A, Sugisawa T, Miyamoto Y, Kishimoto I, et al. Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabet Med. 2009;26:171–3.PubMedCrossRef
56.
Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007;56:960–7.PubMedCentralPubMedCrossRef
57.
Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781–6.PubMedCrossRef
58.
Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes. 2006;55:102–9.PubMedCrossRef
59.
Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21:2644–58.PubMedCentralPubMedCrossRef
60.
Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A. 1990;87:404–8.PubMedCentralPubMedCrossRef
61.
Yuen DA, Zhang Y, Thai K, Spring C, Chan L, Guo X, et al. Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation. Stem Cells Transll Med. 2012;1:921–6.CrossRef
62.
He J, Xu Y, Koya D, Kanasaki K. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol. 2013;17:488–97.PubMedCrossRef
63.
Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19:2282–7.PubMedCentralPubMedCrossRef
64.
Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol. 2009;175:1380–8.PubMedCentralPubMedCrossRef
65.
Wu L, Cox A, Roe C, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor ß1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int. 1997;51:1553–67.PubMedCrossRef
66.
Gilbert RE, Zhang Y, Williams SJ, Zammit SC, Stapleton DI, Cox AJ, et al. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. PLoS One. 2012;7:e47160.PubMedCentralPubMedCrossRef
67.
Gilbert RE, Zhang Y, Yuen DA. Cell therapy for diabetic nephropathy: is the future, now? Semin Nephrol. 2012;32:486–93.PubMedCrossRef
68.
Yuen DA, Connelly KA, Advani A, Liao C, Kuliszewski MA, Trogadis J, et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One. 2010;5:e9543.PubMedCentralPubMedCrossRef
69.
Gilbert RE. Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J. 2013;77:849–56.PubMedCrossRef
70.
Gilbert R. Augmenting endothelial repair in diabetes: role of bone marrow derived cells. Can J Diabetes. 2013;37:315–8.PubMedCrossRef
Metadaten
Titel
The Endothelium in Diabetic Nephropathy
verfasst von
Richard E. Gilbert
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 5/2014
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-014-0410-8

Weitere Artikel der Ausgabe 5/2014

Current Atherosclerosis Reports 5/2014 Zur Ausgabe

Genetics (AJ Marian, Section Editor)

Noncoding RNAs and Atherosclerosis

Genetics (AJ Marian, Section Editor)

Pharmacogenetics of Antiplatelet Therapy

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

Adiposopathy, “Sick Fat,” Ockham’s Razor, and Resolution of the Obesity Paradox

Genetics (AJ Marian, Section Editor)

Dissecting the Causal Genetic Mechanisms of Coronary Heart Disease

Coronary Heart Disease (JA Farmer, Section Editor)

The Role of Nonpharmacologic Device Interventions in the Management of Drug-Resistant Hypertension

Vascular Biology (RS Rosenson, Section Editor)

Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise